Cargando…
Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic
While classic vaccines have proved greatly efficacious in eliminating serious infectious diseases, innovative vaccine platforms open a new pathway to overcome dangerous pandemics via the development of safe and effective formulations. Such platforms play a key role either as antigen delivery systems...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527590/ https://www.ncbi.nlm.nih.gov/pubmed/34687816 http://dx.doi.org/10.1016/j.ijpharm.2021.121212 |
_version_ | 1784586097857134592 |
---|---|
author | Tsakiri, Maria Naziris, Nikolaos Demetzos, Costas |
author_facet | Tsakiri, Maria Naziris, Nikolaos Demetzos, Costas |
author_sort | Tsakiri, Maria |
collection | PubMed |
description | While classic vaccines have proved greatly efficacious in eliminating serious infectious diseases, innovative vaccine platforms open a new pathway to overcome dangerous pandemics via the development of safe and effective formulations. Such platforms play a key role either as antigen delivery systems or as immune-stimulators that induce both innate and adaptive immune responses. Liposomes or lipid nanoparticles, virus-like particles, nanoemulsions, polymeric or inorganic nanoparticles, as well as viral vectors, all belong to the nanoscale and are the main categories of innovative vaccines that are currently on the market or in clinical and preclinical phases. In this paper, we review the above formulations used in vaccinology and we discuss their connection with the development of safe and effective prophylactic vaccines against SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8527590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85275902021-10-20 Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic Tsakiri, Maria Naziris, Nikolaos Demetzos, Costas Int J Pharm Article While classic vaccines have proved greatly efficacious in eliminating serious infectious diseases, innovative vaccine platforms open a new pathway to overcome dangerous pandemics via the development of safe and effective formulations. Such platforms play a key role either as antigen delivery systems or as immune-stimulators that induce both innate and adaptive immune responses. Liposomes or lipid nanoparticles, virus-like particles, nanoemulsions, polymeric or inorganic nanoparticles, as well as viral vectors, all belong to the nanoscale and are the main categories of innovative vaccines that are currently on the market or in clinical and preclinical phases. In this paper, we review the above formulations used in vaccinology and we discuss their connection with the development of safe and effective prophylactic vaccines against SARS-CoV-2. Elsevier B.V. 2021-12-15 2021-10-20 /pmc/articles/PMC8527590/ /pubmed/34687816 http://dx.doi.org/10.1016/j.ijpharm.2021.121212 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tsakiri, Maria Naziris, Nikolaos Demetzos, Costas Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic |
title | Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic |
title_full | Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic |
title_fullStr | Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic |
title_full_unstemmed | Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic |
title_short | Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic |
title_sort | innovative vaccine platforms against infectious diseases: under the scope of the covid-19 pandemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527590/ https://www.ncbi.nlm.nih.gov/pubmed/34687816 http://dx.doi.org/10.1016/j.ijpharm.2021.121212 |
work_keys_str_mv | AT tsakirimaria innovativevaccineplatformsagainstinfectiousdiseasesunderthescopeofthecovid19pandemic AT nazirisnikolaos innovativevaccineplatformsagainstinfectiousdiseasesunderthescopeofthecovid19pandemic AT demetzoscostas innovativevaccineplatformsagainstinfectiousdiseasesunderthescopeofthecovid19pandemic |